drugset / Trial / NCT03867162
FY15-14: Tularemia Vaccine Protocol (NDBR Lot 4)
Phase 2
Withdrawn
U.S. Army Medical Research and Development Command
US Army Medical Research Institute of Infectious Diseases · collab
NaSingle-groupOpen-labelPrevention
Summary
The purpose of this study is to evaluate the safety and immunogenicity of the tularemia vaccine, live, attenuated, NDBR 101, Lot 4, and collect data on the incidence of occupational tularemia infection in vaccinated personnel.
Timeline
- Start
- 2021-06-09
- Primary completion
- 2021-12-17
- Completion
- 2021-12-17
Outcome
Outcome not reported
Stopped (Enrollment): “Sponsor terminated this protocol on Dec17, 2021; no subjects have been enrolled”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NDBR 101 | Unknown | 0.06 ml | Other |